[go: up one dir, main page]

DK3305776T3 - Pyrrol-forbindelser som inhibitorer af erk-protein-kinaser og farmaceutiske sammensætninger, der indeholder disse forbindelser - Google Patents

Pyrrol-forbindelser som inhibitorer af erk-protein-kinaser og farmaceutiske sammensætninger, der indeholder disse forbindelser Download PDF

Info

Publication number
DK3305776T3
DK3305776T3 DK17184079T DK17184079T DK3305776T3 DK 3305776 T3 DK3305776 T3 DK 3305776T3 DK 17184079 T DK17184079 T DK 17184079T DK 17184079 T DK17184079 T DK 17184079T DK 3305776 T3 DK3305776 T3 DK 3305776T3
Authority
DK
Denmark
Prior art keywords
compounds
erk
inhibitors
pharmaceutical compositions
compositions containing
Prior art date
Application number
DK17184079T
Other languages
English (en)
Inventor
Gabriel Martinez-Botella
Michael R Hale
Qing Tang
Judith Straub
François Maltais
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Application granted granted Critical
Publication of DK3305776T3 publication Critical patent/DK3305776T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
DK17184079T 2004-05-14 2005-05-13 Pyrrol-forbindelser som inhibitorer af erk-protein-kinaser og farmaceutiske sammensætninger, der indeholder disse forbindelser DK3305776T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57130904P 2004-05-14 2004-05-14
EP14163944.3A EP2799434B1 (en) 2004-05-14 2005-05-13 Pyrrole compounds as inhibitors of ERK protein kinases and pharmaceutical compositions containing these compounds

Publications (1)

Publication Number Publication Date
DK3305776T3 true DK3305776T3 (da) 2019-12-09

Family

ID=35106760

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17184079T DK3305776T3 (da) 2004-05-14 2005-05-13 Pyrrol-forbindelser som inhibitorer af erk-protein-kinaser og farmaceutiske sammensætninger, der indeholder disse forbindelser

Country Status (25)

Country Link
US (6) US7354939B2 (da)
EP (5) EP3305776B1 (da)
JP (1) JP5132305B2 (da)
CN (1) CN1976919A (da)
AR (2) AR051735A1 (da)
AU (1) AU2005245885B2 (da)
BR (1) BRPI0511111A (da)
CA (1) CA2566461C (da)
CY (1) CY1122336T1 (da)
DK (1) DK3305776T3 (da)
ES (4) ES2513965T3 (da)
HU (1) HUE047130T2 (da)
IL (1) IL179207A0 (da)
LT (1) LT3305776T (da)
MX (1) MXPA06013209A (da)
NO (1) NO20065727L (da)
NZ (1) NZ551582A (da)
PL (1) PL3305776T3 (da)
PT (1) PT3305776T (da)
RU (1) RU2376299C2 (da)
SI (1) SI3305776T1 (da)
TW (1) TW200607803A (da)
UA (1) UA84930C2 (da)
WO (1) WO2005113541A1 (da)
ZA (1) ZA200609975B (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456190B2 (en) * 2003-03-13 2008-11-25 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
WO2005100342A1 (en) * 2004-03-26 2005-10-27 Vertex Pharmaceuticals, Incorporated Pyridine inhibitors of erk2 and uses thereof
PL3305776T3 (pl) * 2004-05-14 2020-03-31 Vertex Pharmaceuticals Incorporated Związki pirolowe jako inhibitory kinaz białkowych erk i kompozycje farmaceutyczne zawierające te związki
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
ES2353437T3 (es) 2006-02-16 2011-03-02 Schering Corporation Derivados de pirrolidina como inhibidores de erk.
PE20090326A1 (es) * 2007-06-05 2009-04-04 Schering Corp Compuestos heterociclos como inhibidores de erk
SG188179A1 (en) 2008-02-21 2013-03-28 Merck Sharp & Dohme Compounds that are erk inhibitors
CN102146074B (zh) * 2011-01-26 2013-02-06 江苏先声药物研究有限公司 吡咯衍生物的制备方法及应用
WO2012172093A1 (en) 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dihydroindolizine derivate as metabotropic glutamate receptor modulators
AU2014337504B2 (en) 2013-10-14 2020-01-30 Indiana University Research And Technology Corporation Use of acamprosate to modulate ERK 1-2 activation in animal models for FXS and ASD and individuals diagnosed with FXS and ASD
EP3061754A4 (en) 2013-10-23 2017-03-22 Takeda Pharmaceutical Company Limited Heterocyclic compound
RU2722784C2 (ru) * 2013-12-20 2020-06-03 Байомед Вэлли Дискавериз, Инк. Лечение злокачественных опухолей с применением комбинаций ингибиторов erk и raf
WO2015095833A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Treatment of hematologic cancers
WO2015095807A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of egfr and erk inhibitors
US20160310477A1 (en) * 2013-12-20 2016-10-27 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of mek type 1 and erk inhibitors
WO2015095835A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods of modulating radioiodine uptake for the treatment of radioiodine-refractory cancers
US11007183B2 (en) 2013-12-20 2021-05-18 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of PI3K/Akt pathway and ERK inhibitors
WO2015095842A2 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
AU2014368927B2 (en) 2013-12-20 2018-10-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of CDK and ERK inhibitors
WO2015095831A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of mtor and erk inhibitors
EP3082779B1 (en) * 2013-12-20 2023-06-07 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of type 2 mek and erk inhibitors
US9676746B2 (en) * 2015-01-30 2017-06-13 Biomed Valley Discoveries, Inc. Crystalline forms of C21H22Cl2N4O2
ES2830044T3 (es) 2015-01-30 2021-06-02 Biomed Valley Discoveries Inc Malonato de C21H22C12N4O2 cristalino
WO2016187028A1 (en) * 2015-05-15 2016-11-24 Celgene Avilomics Research, Inc. Heteroaryl compounds, synthesis thereof, and intermediates thereto
EP3303335B1 (en) * 2015-06-03 2021-07-28 JS Innopharm (Shanghai) Ltd. Heterocyclic compounds for treating psoriasis
CN107849046B (zh) * 2015-06-03 2020-06-12 常州捷凯医药科技有限公司 作为erk抑制剂的杂环化合物
EP3365334B1 (en) 2015-10-21 2024-07-17 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
EP3170822A1 (en) 2015-11-18 2017-05-24 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
BR112019005305A2 (pt) * 2016-10-05 2019-07-02 Zeno Royalties & Milestones Llc compostos espirocíclicos
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
JP7332589B2 (ja) * 2017-10-12 2023-08-23 ノバルティス アーゲー 癌を治療するためのｍｄｍ２阻害剤とｅｒｋの阻害剤との組合せ
WO2019180141A1 (en) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinations of rogaratinib
US20230190725A1 (en) * 2019-04-29 2023-06-22 The Board Of Trustees Of The University Of Illinois Mek inhibitors for corneal scarring and neovascularization
WO2021020841A1 (en) * 2019-07-29 2021-02-04 Standigm Inc. Composition for preventing or treating metabolic liver disease
EP4212531A1 (en) 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
CN118765276A (zh) * 2022-03-08 2024-10-11 甘李药业股份有限公司 氘代化合物，及其制备方法和应用
CN119212985A (zh) * 2022-03-24 2024-12-27 生物医学谷探索股份有限公司 Erk的吡咯抑制剂的氘代类似物、其合成及其中间体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US5565413A (en) * 1994-12-06 1996-10-15 Zeneca Limited Substituted pyridyl phenyl ketone herbicides
US5472966A (en) * 1995-03-29 1995-12-05 Bristol-Myers Squibb Company Antidepressant heteroarylaminoalkyl derivatives of naphthyl-monazines
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
CN1210273C (zh) * 1999-05-14 2005-07-13 奥索-麦克尼尔药品公司 取代的3－吡啶基－4－芳基吡咯及治疗和预防相关疾病的方法
WO2000078747A1 (en) * 1999-06-22 2000-12-28 Takeda Chemical Industries, Ltd. Acylhydrazine derivatives, process for preparing the same and use thereof
MY130778A (en) 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
WO2003091246A1 (en) * 2002-04-26 2003-11-06 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
CA2491895C (en) * 2002-07-09 2011-01-18 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
WO2004009562A1 (en) 2002-07-18 2004-01-29 Janssen Pharmaceutica, Nv Substituted triazine kinase inhibitors
GB0217780D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
RU2005106871A (ru) * 2002-08-14 2005-10-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы протеинкиназ и их применение
US7456190B2 (en) * 2003-03-13 2008-11-25 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
PL3305776T3 (pl) * 2004-05-14 2020-03-31 Vertex Pharmaceuticals Incorporated Związki pirolowe jako inhibitory kinaz białkowych erk i kompozycje farmaceutyczne zawierające te związki

Also Published As

Publication number Publication date
USRE47318E1 (en) 2019-03-26
AU2005245885B2 (en) 2011-01-20
EP1753738B1 (en) 2014-07-09
USRE48266E1 (en) 2020-10-20
NZ551582A (en) 2011-01-28
ES2513965T3 (es) 2014-10-27
WO2005113541A1 (en) 2005-12-01
EP3305776B1 (en) 2019-09-25
HK1203505A1 (en) 2015-10-30
US7354939B2 (en) 2008-04-08
BRPI0511111A (pt) 2007-11-27
EP1753738A1 (en) 2007-02-21
US20230183276A1 (en) 2023-06-15
NO20065727L (no) 2006-12-12
AU2005245885A1 (en) 2005-12-01
ES2651439T3 (es) 2018-01-26
MXPA06013209A (es) 2007-01-16
RU2376299C2 (ru) 2009-12-20
EP3608315B1 (en) 2021-08-11
EP3305776A1 (en) 2018-04-11
EP3608315A1 (en) 2020-02-12
TW200607803A (en) 2006-03-01
ES2897422T3 (es) 2022-03-01
ES2751761T3 (es) 2020-04-01
UA84930C2 (ru) 2008-12-10
EP2799434A1 (en) 2014-11-05
RU2006144445A (ru) 2008-06-20
USRE49500E1 (en) 2023-04-25
US20060106069A1 (en) 2006-05-18
AR051735A1 (es) 2007-02-07
JP2007537295A (ja) 2007-12-20
JP5132305B2 (ja) 2013-01-30
CA2566461A1 (en) 2005-12-01
PT3305776T (pt) 2019-12-17
HUE047130T2 (hu) 2020-04-28
EP2799434B1 (en) 2017-08-02
USRE46097E1 (en) 2016-08-09
PL3305776T3 (pl) 2020-03-31
LT3305776T (lt) 2020-01-10
SI3305776T1 (sl) 2020-01-31
AR106755A2 (es) 2018-02-14
CY1122336T1 (el) 2021-01-27
IL179207A0 (en) 2007-03-08
EP3943489A1 (en) 2022-01-26
CA2566461C (en) 2012-07-10
ZA200609975B (en) 2008-02-27
HK1247910A1 (en) 2018-10-05
CN1976919A (zh) 2007-06-06

Similar Documents

Publication Publication Date Title
DK3305776T3 (da) Pyrrol-forbindelser som inhibitorer af erk-protein-kinaser og farmaceutiske sammensætninger, der indeholder disse forbindelser
DK1713806T3 (da) Forbindelser og sammensætninger som proteinkinaseinhibitorer
DK1664043T3 (da) Sammensætninger egnede som inhibitorer af proteinkinaser
DK2076260T3 (da) N-methylaminomethyl-isoindol-forbindelser og sammensætninger, der indeholder disse, samt fremgangsmåder til deres anvendelse
DK1562589T3 (da) Diaminotriazoler der er nyttige som inhibitorer af proteinkinaser
DK1962830T3 (da) Azaindolhæmmere af aurorakinaser.
DK1888584T3 (da) Tricykliske 1,6-dihydro- 1,3,5,6-tetraaza-as-indacen-baserede forbindelser og farmaceutiske sammensætninger omfattende samme som hæmmere af IKK-enzymaktivitet
DK2039685T3 (da) Heterobicycliske forbindelser som P38-inhibitorer
DK1928879T3 (da) Kondenserede heterocykliske forbindelser og anvendelse heraf som kinase-modulatorer
NO20082256L (no) Pyrazolderivater, preparater som inneholder slike forbindelser, og fremgangsmåter for anvendelse
DK1848694T3 (da) Heterocykliske substituerede phenylmethanoner som inhibitorer af glycintransporter
DE602005025733D1 (de) Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
DK1756064T3 (da) Pyrazolderivater, sammensætninger indeholdende sådanne forbindelser og anvendelsesmetoder
DK1945631T3 (da) 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer
DK1480644T3 (da) Heterocykliske forbindelser, der er aktive som inhibitorer af beta-lactamaser
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
DK1730146T3 (da) Azaindoler anvendelige som inhibitorer af JAK og andre proteinkinaser
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
DK1711481T3 (da) Fremgangsmåde til fremstilling af 2-aminothiazol-5-aromatiske carboxamider som kinaseinhibitorer
DK1758914T3 (da) Hidtil ukendte fluorglycosidderivater af pyrazoler, lægemidler indeholdende disse forbindelser og anvendelse heraf
DK1877232T3 (da) Fremgangsmåde til behandling af træoverflader
DK1585749T3 (da) Diazepinoindol-derivater som kinaseinhibitorer
SE0701538L (sv) Azaspiroalkanderivat som hämmare av metalloproteaser
DK2021335T3 (da) Heterocykliske forbindelser som C-FMS-kinasehæmmere
DK1761505T3 (da) Pyrimidin-urinstof-derivater som kinaseinhibitorer